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Amphetamine and its derivatives’ consumption is still an important public health issue, 
namely in terms of compounds variability and disposition to consumers. However, some of 
them, like MDMA, still live in the illicit market, with continuous success. Nevertheless, there 
is always new information and data on MDMA intoxication, both in vivo and in post-mortem 
context. 
The authors report an intoxication case with MDMA, in an 18 years old male, considered a 
potential organ donor after a cardiac arrest. Whole blood samples were collected in vivo, at 
the Emergency Room (ER), and post-mortem, at the National Institute of Legal Medicine and 
Forensic Sciences. 
After a general screening procedure, samples were extracted by SPE (OASIS® MCX), 
followed by GC-MS analysis. The whole blood post-mortem sample was positive for 
lidocaine (< 500 ng/mL), compatible with the ER intervention, and positive for MDMA (2278 
ng/mL) and MDA (49 ng/mL), while whole blood samples collected in vivo (during the 
maintenance of the individual under advanced life support), were positive for MDMA (504 
ng/mL to 1918 ng/mL) and MDA (20 ng/mL to 89 ng/mL). Samples were negative for other 
substances, namely ethanol, other drugs of abuse and medicines. 
Results interpretation is pivotal to understand the behaviour of the substance. Thus, in this 
case, MDMA post-mortem behaviour should be carefully evaluated, considering as possible 
influencers, in the specific context of the case, the time lapse between death verification, 
maintenance of the advanced life support and body manipulation for organ collection 
purposes. Also referred and discussed is the ante-mortem/post-mortem ratio of MDMA 
obtained values, compared with literature references. There is no doubt that death was due to 
MDMA intoxication, but information from the analysis performed on the in vivo samples 











3,4-Methylenedioxymethamphetamine (MDMA), or “Ecstasy”, is a derivative of 
methamphetamine. It represents a class of psychoactive agents called entactogens, which 
produce feelings of closeness to others and empathy, well-being, and insightfulness, alongside 
with the physical effects of enhanced energy, endurance, sociability, and sexual arousal (1). 
MDMA is typically consumed orally, being used alone or mixed with other substances, 
including ethanol. Adverse effects are generally known, and can be very different, being 
coma, hyperpyrexia and cardiovascular compromise the most usual ones. However, MDMA-
related deaths are unpredictable, both in terms of ingestion quantities as in terms of acute or 
chronic consumption (2). 
Cardiac arrest (CA) is a catastrophic event with a high mortality rate. In some cases, 
intervention by extracorporeal CPR (eCPR: extracorporeal cardiopulmonary resuscitation) 
does not avoid an anoxic brain injury, evolving to brain death (BD) and, potentially, to organ 
donation (3). In Portugal, the law determines that every citizen is a potential organ donor, 
unless clearly expressed by the individual when alive, through a specific written form, under 
the Portuguese Blood and Transplantation Institute management. Thus, whenever an 
individual is considered dead, mainly in ER or Intensive Care Units, he/she becomes 
eventually a potential donor. 
In this paper, the authors report an intoxication case with MDMA in an 18 years old male, 
who was considered a potential organ donor, after a cardiac arrest. The obtained values, both 
“in vivo”, under eCPR, and post-mortem are discussed, along with some discussion on the 
ante-mortem/post-mortem ratio, among other potential issues. 
 
2. Case Report 
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An emergency call was received (9 a.m.) reporting that a 18 years old male was found 
uncouncious in his car, with some signs of violence inside it. An intoxication suspicion was 
considered. At 9.17 a.m., an emergency team arrived and observed the existence of stridor, 
mydriasis and hiperthermia (tympanic temperature: 42ºC). He was brought to the Hospital 
Emergency Room, and was declared death at 10.13 a.m., classified as a potential organ donor, 
and was maintained under eCPR until organ collection, which was performed between 2 p.m. 
and 4 p.m.. Autopsy was performed in the next day, at the Forensic Pathology Service of the 
North Branch of the National Institute of Legal Medicine and Forensic Sciences. Whole blood 
samples were collected in vivo, at the Hospital Emergency Room (ER), in different moments, 
as well as post-mortem, during the autopsy procedure. 
 
3. Material and Methods 
3.1. Materials, standards and chemicals 
Pure MDMA, MDA and deuterated internal standards (MDMA-D5 and MDA-D5) were 
purchased from Cerilliant Corporation (Round Rock, TX, USA). Working solutions at 
concentrations of 0.5 mg/L and 5 mg/L were prepared in methanol and stored at -20ºC. 
Methanol (gradient grade), HCl 37%, KH2PO4, dichloromethane, 2-propanol and NH4
+ were 
purchased from Merck (Darmstadt, Germany). The derivatization reagent [MBTFA: N-
Methyl-bis(trifluoroacetamide)] was purchased from Macherey-Nagel (Duran, Germany). 
OASIS® MCX columns were purchased from WATERSTM (Milford, MA, USA). The 
analytical apparatus included an Agilent 6890 GC, coupled to an Agilent 5973n MS. 
 
3.2. Samples preparation and analysis 
A method for amphetamine-type substances was applied. Twenty-five µL of internal standard 
solution (50 ng/mL per sample) were added to 4 mL of KH2PO4 0,1M buffer solution. A 500 
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µL whole blood aliquot, previously agitated in a roller mixer for 15 min, was added to the 
above mixture. The sample was vortexed and centrifuged at 4000 RPM, for 30 min. SPE 
procedure, using OASIS MCX columns, included the following steps: cartridge conditioning 
with 2 mL of methanol and 2 mL of deionised water. The sample was loaded onto the 
conditioned cartridge and allowed to drain at a 1–2 mL/min flow. Washing steps were 
performed sequentially with 2 mL of deionised water, 2 mL of HCl 0,1M, 3 mL of a 
dichloromethane/methanol solution (70:30, v/v), 3 mL of n-hexane and vacuum drying was 
performed for 15 min. After that, an elution step was performed, with 2 mL of 
dichloromethane/2-propanol/NH4
+ (78:20:2, v/v/v) mixture. Samples were evaporated to 
dryness at 45ºC, in a TurboVap evaporator. After evaporation, 60 µL of BSTFA:TMCS (99:1) 
were added, and the sample consequently vortexed. The derivatization was performed at 65ºC 
for half an hour, followed by instrumental analysis using GC–MSD single quad (Table 1 and 
Table 2). This method was previously validated and applied to routine determination of 
amphetamines (data not published). Some of the validation parameters are briefly described at 
Table 3. 
 
4. Results and discussion 
 The in vivo samples were collected after death verification and under eCPR. The post-
mortem sample was collected at autopsy. The obtained values are shown in Table 4. The post-
mortem whole blood sample was also positive for lidocaine (< 500 ng/mL), compatible with 
advanced life support intervention. All the samples were negative for other substances, 
namely other illicit compounds, ethanol and medicines. 
Results interpretation is always a quest with specific issues, deep related to each case. Firstly, 
the presence of MDA and MDMA is compatible with MDMA consumption, with MDA as a 
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metabolite, with a much lower concentration. Both compounds’ ratio (0,021) at the post-
mortem level supports this assumption, when compared with the literature (4,5). 
On the other hand, postmortem/antemortem (PM/AM) values ratio is also an issue, which has 
been discussed for some compounds. The literature refers that there is an apparent rise in 
MDMA concentrations in blood after death, regardless the postmortem collection site (5). 
However, the subsequent increasing of the concentration may vary, depending on the 
anatomical site, indicating possible redistribution. In other similar situations, with Hospital 
admission prior to death, Elliott reports ratios between 1.1 and 2.8 (5). 
However, and in this particular case, the eCPR maintenance can be a problem, since it allows 
further MDMA metabolization, even after when death is declared. Thus, it must be noted that 
MDMA concentration increases to a maximum of 1918 ng/mL and decreases again, in an 
approximately two hours time-lapse. In a typical metabolic profile, MDMA shows a tmax (time 
after ingestion, at which the plasma concentration is maximal) of 2 hours and a t1/2 from 5 to 
10 hours (6,7). Considering that medical intervention started about 1.5 – 2 hours before the 
first sample collection, the results seem consistent to these reference values. 
After eCPR maintenance, organ collection procedure started about two hours after the last in 
vivo collected sample. It is known that MDMA and other amphetamine-type stimulants are 
fond to some post-mortem redistribution, even though mainly observed in heart blood, as it is 
more easily exposed to post-mortem redistribution and can, therefore, be misleading in the 
interpretation of a toxic or lethal post-mortem concentration (8). On the other hand, and due 
to the fact that MDMA can accumulate in various tissues and organs (8), a procedure like an 
organ collection can potentially alter, in a dramatic way, the “usual” course of MDMA post-
mortem behavior. 
In practical terms, it is generally accepted that MDMA blood concentration, alone, is not an 
unequivocal sign of the death mechanism, with cases reporting values from 600 ng/mL to 
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84000 ng/mL, depending, among other factors, on age, health general status, (in)existence of 
symptoms related with hypersensitivity reactions and route of administration (9,10). 
Moreover, fatalities are not apparently directly linked to dosage and ingestion time-lapse (10). 
Still, the detected concentration is compatible with an intoxication, when compared to the 
existing literature (11,12). Moreover, and according to the literature, the obtained PM/AM 
ratio is also consistent with an MDMA intoxication (5), allowing to conclude that the death 
was due to a MDMA accidental intoxication, and that, in this case, the organ collection 
procedure did not change the course of facts in a dramatic way. 
 
5. Conclusion 
The obtained results suggested MDMA intoxication as the cause of death, based on the 
identification of the substance, the obtained value, and histological alterations, namely the 
presence of edema in the pulmonary tissue histology. The different values obtained during the 
mechanical ventilation and other life-support measures show that MDMA was still being 
metabolized. Thus, information on this procedure should always be transmitted to the medico-
legal experts. Post-mortem interval is an important point of discussion, concerning 
toxicological results and interpretation. In this particular case, the increased MDMA 
concentration observed in the PM sample, and after studying the PM/AM ratio, is coherent 
with previous studies. Nevertheless, the body manipulation needed for organ collecting 
procedures can alter PM redistribution, influencing the quantitative result for the substance. 
Therefore, MDMA post-mortem behaviour should be carefully evaluated, considering as 
possible influencers, in the specific context of the case, the time lapse between the death 
verification, the maintenance of the advanced life support and the body manipulation for 
organ collection purposes. The post-mortem/ante-mortem ratio of MDMA obtained values, 
compared with literature references, also supports the conclusions. No doubt that death was 
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due to MDMA intoxication, but information from the in vivo samples analysis suggests that 
this type of sample should also be considered, in a complementary role, whenever possible. 
Consequently, the authors consider that communication between the medico-legal services 
and Hospital departments can be decisive, in order to obtain samples collected as closer to the 
event as possible, as well as all the medical data available, in order to know all the procedures 
that were performed in the victim which can influence the final outcome, to determine in a 
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Table 1 - Instrumental conditions. 
 
 GC-MSD Single Quad 
GC AGILENT 6890N 
MS AGILENT 5973N 
Chromatographic 
separation 
J&W Scientific 5-ms, 30 m x 0,25 mm x 0,25 µm 
Tinjector: 250ºC 
90ºC for 1 min, to 200ºC at 25ºC/min, plateau for 4 min to 
290ºC at 30ºC/min, plateau for 2 min 
Detector 
Direct interface; Internal Ionization by EI; Ttransferline: 280ºC 
Tquadrupole: 150ºC; SCAN mode, dwell time 1 sec/scan; 









MDA 135, 162, 275 
MDA-D5 167 










Validation parameter MDA MDMA 
LOD (ng/mL) 10 10 
LLOQ (ng/mL) 25 25 
Recovery (%) 90 89 
Linearity / workrange (ng/mL) 25 - 1000 25-1000 





Table 4 – Sampling time and obtained results 
Sampling time MDA (ng/mL) MDMA (ng/mL) Ratio PM/AM 
10H45 – ER – AM Neg 504 4.52 
11H34 – ER – AM 89 1918 1.19 
12H48 – ER – AM 20 1359 1.68 
Day 2 – 14H00 – PM 49 2278 - 
ER – Emergency Room (in vivo); AM – Antemortem; PM – Postmortem 
 
